Brief: In8bio Presents Positive, New Inb-100 Data Showing Long-Term Complete Remissions And Elevated Gamma-Delta T Cells In 100% Of Evaluable Treated Leukemia Patients At Ebmt 2023
24/04/2023 13:20
April 24 (Reuters) - IN8BIO, Inc. INAB.O :
* IN8BIO PRESENTS POSITIVE, NEW INB-100 DATA SHOWING
LONG-TERM
COMPLETE REMISSIONS AND ELEVATED GAMMA-DELTA T CELLS IN 100% OF
EVALUABLE TREATED LEUKEMIA PATIENTS AT EBMT 2023
Source text for Eikon: ID:nGNX46TcZW
Further company coverage: INAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall